Author:
Topaly J,Zeller WJ,Fruehauf S
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference32 articles.
1. Sawyers CL . Chronic myeloid leukemia N Engl J Med 1999 340: 1330–1340
2. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL . Clinical efficacy and safety of an Abl-specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia Blood 1999 94: (Suppl. 1) 368a
3. Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ . Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors Cancer Chemother Pharmacol 1999 44: 433–438
4. Schiedlmeier B, Kühlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S . Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice Blood 2000 95: 1237–1248
5. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S . An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology Blood 1999 94: 1517–1536